A critical issue for E1-deleted adenoviral vectors manufactured from 293 cells is the emergence of replication-competent adenovirus (RCA). These contaminants arise through homologous recombination between identical sequences framing the E1 locus displayed by 293 cells, and the vector backbones. Modified recombinogenic sequences (syngen) were thus introduced within the vector backbone, and virus viability and RCA emergence were assessed. Syngen#1 is a synthetic sequence displaying silent point mutations in the pIX and IVa2 coding regions. A side by side comparison of Ad5CMV/p53 (E1-deleted adenovirus expressing the p53 tumor suppressor gene) and AV⌬E1#1CMV/p53 (with syngen#1 in place of wild-type sequences) demonstrated a
Introduction
Subgroup C-based adenoviral vectors are being used in a growing number of clinical trials for acquired (eg cancer) and monogenic hereditary disorders. Because these serotypes induce a lytic productive infection in a wide range of human cell types, first-generation gene therapy vectors have been disabled by deleting the E1 regulatory genes from the viral chromosome. 1 Accordingly, first-generation vectors must be amplified in human cells capable of efficiently transcomplementing for the missing E1 genes. Most of clinical grade preparations of E1-deleted recombinant vectors are carried out in 293, a cell line of human embryonic origin that displays the Ad5 E1 locus and flanking sequences. 2 These cells harbor the left 12% of the Ad5 genome (up to nt position 4344), thereby encompassing the entire E1 locus. 3 Unfortunately, identical/recombinogenic sequences on both sides of the E1 genes allow the vector to reacquire the E1 genes by homologous recombination during virus growth. [4] [5] [6] Contamination of clinical lots with E1+ replication-competent adenovirus (RCA) raises specific safety issues due to the lytic nature of Ad5. Also, exacerbation of host inflammatory responses with significant tissue damage and pathogenicity has been assigned to such autonomous contaminants. 4, 5, 7 In practice, a significant proportion of clinical batches cannot be used because RCA contamination exceeds levels specified by the Food and Drug Administration. 8 Cell-or vector-based solutions have been proposed to decrease the occurrence of homologous recombination which triggers the emergence of RCA during amplification of E1-deleted recombinants. 5, 9 In particular, human embryonic retinoblasts have been engineered that harbor minimal E1 sequences (nt Ad5 position 459 to 3510) integrated in the cellular chromosome. Importantly, PERC6 cells can efficiently rescue E1-deleted (first-generation) adenoviral vectors with no detectable RCA contamination. 9 Ideally, the PERC6 strategy requires extended E1 deletions within the vector backbone. 9 Also, this cell line is not appropriate to produce second-generation adenoviral vectors harboring a second lethal deletion. 10 Another approach relies on modifying the overall architecture of the virus chromosome so that homologous recombination between the vector and 293 recombinogenic sequences occurs at a lower frequency. For example, the pIX recombinogenic sequences can be relocated at the right end of the viral chromosome so that homologous recombination within the pIX sequence of 293 cannot generate an autonomous virus. 5 Here, we report another vector-based strategy that sig-nificantly reduces RCA emergence in 293 without remodeling the overall architecture of the recombinant chromosome. To this end, 'silent' modifications were introduced within the vector backbone to lower the frequency of pairing and strand exchange during homologous recombination (HR). Indeed, all HR models share a common DNA strand exchange mechanism following pairing between identical DNA stretches. [11] [12] [13] Importantly, the length of homologous sequence between the two strands is a key parameter that dictates the rate of HR, 14, 15 and base pair mismatches drastically decrease the rate of HR. 15, 16 We show here that incorporation of 'silent' mutations within the adenoviral vector sequences significantly decrease RCA emergence during virus growth in 293 cells without altering vector productivity.
Results

Synthetic sequence design
Silent mutations were introduced in the pIX and IVa2 region. Redundancy of the codon usage was exploited so as to introduce silent mutations within the pIX and IVa2 open-reading frames. We first established a codon usage table for adenovirus serotype 5. Data from 10 Ad5 proteins (pIX, hexon, pIII, pVII, 53-55K, AdPol, pTP, DBP, 23K, 19K) were thus compiled (data not shown) and compared with the codon usage for human proteins (ftpadm@bioneer.kaist.ac.kr). Only minor differences were found. The following rules were then used for mismatch introduction: (1) the most preferred codon was always incorporated in the syngen whenever possible; (2) the second most used codon was incorporated when the most preferred codon was already used in the Ad5 sequence. In some cases, a third prefered codon was used when its frequency was similar to that of the second preferred codon.
For syngen#1, boundaries of the synthetic sequences were Ad5 positions 3520 (ie 56 nt upstream of the pIX promoter) and 4445 (ie location of a NruI site within the IVa2 coding sequence that was used for cloning purposes). Syngen#1 was introduced in place of the native pIX-IVa2 sequences on a ⌬E1 first-generation vector expressing the p53 gene from the CMV IE promoter (virus AV⌬E1#1CMVp53). This virus was thus designed to be identical to virus Ad5CMV/p53, except for the pIXIVa2 sequences in which silent mutations were introduced between position 3520 to 4445, thereby disrupting the sequence homology with the pIX-IVa2 sequences present in the genome of 293 cells. Plasmid pAd⌬E1#1CMVp53 which contains a PacI-excisable ⌬E1 adenoviral chromosome driving p53 expression from the CMV IE promoter was then constructed by recombinational cloning in E. coli. 17 The corresponding virus, AV⌬E11#1CMVp53, was recovered following transfection of 293 cells. 17 As shown in Figure 1 , the maximum of length of identical stretches in the pIX-IVa2 region between the 293 cell genome and the classical recombinant adenoviral vector vectors (eg Ad5CMVp53) is reduced from 898 nt to 92 nt in the novel context (eg virus AV⌬E1#1CMVp53).
The syngen#1 mutations are phenotypically silent
Since p53-mediated apoptosis may affect virus growth during amplification in 293, we speculated that this parti- cular transgene expression could influence the selection pressure leading to the take over of (E1+; p53-) RCAs during virus growth.
First, we compared p53 expression levels and functionality following infection with both vectors Ad5CMVp53 and AV⌬E1#1CMVp53 vectors. Similar p53 expression levels from both constructs were documented by Western blot analysis of extracts from H1299-infected cells (MOI = 4300 vp/cell) (data not shown). AV⌬E1#1CMVp53 and its 'isogenic' control also triggered a similar transgene-specific cytotoxicity in this tumor cell line model, as shown in Figure 2a , H1299 infection with AV⌬E1#1CMVp53 and Ad5CMVp53 triggered similar dose-dependent cytotoxicity 72 h after infection, as compared with that of AV⌬E1Empty (no transgene expressed).
Two consecutive batches were then prepared in parallel from AV⌬E1#1CMVp53 and Ad5CMVp53 seedstocks. The titers were expressed as viral particles and as plaque forming units on to 293 cells. For both viruses, the vp/PFU ratio was similar (ranging from 66 to 84). The same also applied for virus productivity: following infection at an MOI of 150 vp/cell (MOI = 150 vp/cell), the yields ranged from 7.5 × 10 11 to 1.1 × 10 12 vp/ml for Ad5CMVp53, and 9.3 × 10 11 to 1.3 × 10 12 vp/ml for AV⌬E1#1CMVp53 (1.5 ml of purified virus from 4. for AV⌬E1#1CMVp53 (n = 20). From these two sets of data, we concluded that the silent nature of the mutations introduced within syngen#1 did not significantly affect the viral growth. We then assessed whether the introduced syngen#1 mutations led to appropriate expression of the pIX and IVa2 genes. Expression levels were thus analyzed in extracts prepared from 293-infected cells (MOI = 150 vp/cell) using anti-pIX and anti-IVa2 antibodies. 18 In sharp contrast to mock-infected cell extracts for which
Figure 2 Compared analyses in Western blot and in cell viability assay of AV⌬E1#1CMVp53 or Ad5CMVp53 viruses. (a) Western analysis of IVa2 proteins in extracts of 293 cells infected by AV⌬E1#1CMVp53 or Ad5CMVp53. Noninfected 293 cells extracts were used as a control. (b) Western analysis of pIX proteins using purified virions of AV⌬E1#1CMVp53 or Ad5CMVp53. The 55 kDa IVa2 protein and the 14 kDa pIX protein were detected as described in Materials and methods. (c) Cell viability assay. H1299 cells were infected with the indicated viruses and cell viability was determined at different times after infection in the trypan blue exclusion assay as described in Materials and methods. Results are shown as mean of duplicate determinations with standard deviations.
there was no pIX-or IVa2-reactive material, similar levels of IVa2 were detected in AV⌬E1#1CMVp53 and Ad5CMVp53-infected extracts ( Figure 2b and data not shown). pIX incorporation within the viral capsids was also unaffected by the syngen#1 mutations ( Figure 2c ).
Statistical analysis of RCA emergence
RCA emergence was then analyzed following AV⌬E1#1CMVp53 and Ad5CMVp53 amplifications in 293 cells. To this end, five plaque-purified viruses (C1-C5) for each construct were amplified in parallel on to 293 cells (Table 1 ) according to the scheme described Figure 3 (seven consecutive amplification steps from amplification 1 (P1) to amplification 7 (P7)). RCA contamination was then quantified in triplicate assays using the 10 samples at a dose of 3 × 10 10 vp, and by quantifying the number of plaque-forming units following infection of A549 cells at an MOI below to 200 vp/cell. Values of 0, 1 or 2 RCAs were found when the P7-amplified samples of C2 and C4 plaques of the Ad5CMVp53 virus were tested in triplicate. Also, a total of six RCAs was found for the Ad5CMVp53-derived samples, whereas no RCA could be detected for the AV⌬E1#1CMVp53-derived samples. The six RCA plaques were then amplified on A549 cells, viral DNA was extracted 10 and characterized by DNA restriction analysis. As predicted from the Gene Therapy emergence of RCA by homologous recombination between the 293 and the viral backbone, the six RCAs that arose during amplification of the Ad5CMVp53 vector had reacquired the E1 genes in place of the transgene expression cassette.
Statistical analyses were performed (r = 6; fmax = 0.648; P value = 0.015; see Materials and methods), demonstrating a significant improvement of the AV⌬E1#1CMVp53 compared with the Ad5CMVp53, in terms of RCA emergence during propagation on 293 cells.
Introduction of extended mutations
During the course of this study, the Ad5 sequence integrated in the 293 genome was reported to extend up to position 4344 in the IVa2 gene.
3 Accordingly, syngen#2 was designed to incorporate silent mutations up to position 4343. In this novel synthetic sequence, the pIX/IVa2 noncoding sequences were also modified: (1) eight point mutations were introduced within the pIX promoter further reducing the maximal length of identical sequences from 92 nt in syngen#1 context down to 29 nt in syngen#2 context (Figure1); and (2) the pIX/IVa2 intergenic region of Ad5 (nt position 4033 to 4090) was also replaced with its counterpart from adenovirus serotype 7 (nt position 3897 to 3948).
19 Syngen#2 was then introduced by recombinational cloning in E. coli in the backbone of an E1, E3-deleted adenoviral genome carrying a LacZ expression cassette (pAd⌬E1#2CMVLacZ).
Transfection of PacI-restricted pAd⌬E1#2CMVLacZ in 293 cells led to the recovery of the expected adenovirus (AV⌬E1#2CMVLacZ). Expression of pIX and IVa2 genes were first analyzed in extracts prepared from 293-infected cells (MOI = 150 vp/cell) using anti-pIX and anti-IVa2 antibodies. 18 As shown in Figure 4a , similar levels of IVa2 were detected in AV⌬E1#2CMVLacZ-and AV⌬E1CMVLacZ-infected extracts. Incorporation of the pIX polypeptide within the viral capsids was also unaffected by the syngen#2 mutations (Figure 4b ). Finally, virus productivity was not significantly affected by these mutations ( Table 2) . Productivity of two additional constructs (AV⌬E1#2-Empty and AV⌬E1#2CMVLUC) was also unaffected by the incorporation of the syngen#2 sequence (data not shown).
Also, when syngen#2 was introduced in a doubledeleted ⌬E1E4 adenoviral vector, titers were also unaffected (AV⌬E1E4#2CMVLacZ versus AV⌬E1E4LacZ, its pIXIVa2 nonmodified control virus) (data not shown).
Discussion
Amplification of first-generation vectors in 293 cells inevitably generates autonomous particles (RCA) in which the Ad5 E1 sequences of the 293 producing cells have jumped back on to the vector chromosome in place of the transgene expression cassette. [4] [5] [6] Accordingly, a significant proportion of clinical-grade recombinant adenovirus preparations cannot be used due to RCA contamination beyond the tolerated levels recommended by the Food and Drug Administration for clinical samples. 8 A new approach to reduce or abolish RCA emergence is proposed here. This approach is based on the modification of recombinogenic sequences in order to interfere with homologous recombination mechanisms. Sequence homology is a prerequisite for HR events. Mechanistic models share in common the pairing of two DNA frag- Five plaque-purified viruses (C1-C5) for both virus were amplified through seven passages. Passages 1, 2 and 3 were performed using MW24-well, MW6-well cluster plate and 100 mm diameter dishes, respectively. After passage 3, virus production was assessed by HPLC. For passage 4, the cells were infected at an MOI of 50 vp/cell for the subsequent passages, an MOI of 100 vp/cell was applied. Total cell numbers and vp production are provided whenever available. ments with the same or almost the same sequences. [11] [12] [13] Experimental works showed that the frequency of HR is a function of the homology length. 14, 20, 21 Moreover, introduction of base pair mismatches can reduce homologous recombination events. 15, 16 Taking into account these data, regularly spaced base pair mismatches were thus introduced within the adenoviral chromosome to study its impact on virus productivity and RCA emergence during virus amplification in 293 cells.
Using the genetic code degeneracy, introduced mutations were first confined to the pIX and IVa2 coding sequences in the first version (syngen#1), and were silent (ie they did not change the pIX and IVa2 primary sequences). An AV⌬E1#1-CMVp53 vector was constructed and was shown to display normal productivity and lead to a significant improvement in terms of RCA emergence as compared with a standard, unmodified vector Ad5CMVp53 containing the same p53 expression cassette. The viability of this first construct prompted us to generate a AV⌬E1#2 backbone. In this more advanced version (syngen#2), additional mutations were introduced in the noncoding region of the pIX gene. Consequently, the maximum of uninterrupted stretches of homology with the 293 cell E1 downstream sequences was decreased from more than 800 bp for standard vector, down to 29 bp in the AV⌬E1#2 vector. The AV⌬E1#2 vectors were shown to harbor the same productivity as the classical vectors in 293 cells.
Mapping of the Ad5 sequences in the 293 cell genome indicated at least 400 bp upstream and approximately 850 pb downstream the E1 region of homologous sequence between the genome of standard vector and that of 293 cell. 3 Characterization of Ad2-Ad5 chimera showed that dual recombination events predominate in the generation of RCA resulting in loss of the transgene and reacquisition of the E1 region. 5 Accordingly, a previous approach to this problem included the relocation of the pIX region to the right end of the virus. Even though 324 bp of continuous homology remained between the vector and the E1 sequences from 293, the frequency of RCA emergence was shown to be diminished. 5 In our strategy, the maximum length of homology between the vector backbone and the 293 genome downstream the E1 region was first reduced to 92 nt (syngen#1). To validate this approach in terms of RCA occurrence, the AV⌬E1#1CMVp53 vector was compared with an 'isogenic' ⌬E1 first-generation vector expressing the p53 transgene from the CMV IE promoter (Ad5pCMVp53). AV⌬E1#1CMVp53 viability was clearly unaffected by incorporation of the synthetic sequences. First, its productivity was very similar to that of Ad5pCMVp53, its 'isogenic' control virus. Second, pIX and IVa2 biosynthesis were not modified during packaging in 293 cells and pIX incorporation into the virus capGene Therapy sids remained unchanged. Most importantly, incorporation of syngen#1 in place of the native pIX-IVa2 sequences significantly reduced RCA emergence during virus amplification in 293 cells. Indeed, RCA were never detected in conditions that led to the identification of six positive samples of Ad5CMVp53. Statistical analysis of these results indicated a significant reduction of RCA emergence following incorporation of syngen#1 (P Ͻ 0.015).
It must be noted that two stretches of sequences in syngen#1 remained identical to the 293 genome, including 92 nt within the pIX promoter, and 63 nt corresponding to the pIX-IVa2 intergenic sequence. These potentially recombinogenic sequences were thus modified by incorporating additional mismatches within syngen#2. In this version, point mutations in the coding region were slightly different but most importantly, point mutations were introduced within the pIX promoter and the pIXIVa2 polyA region was exchanged with the pIX-IVa2 polyA region from Ad7. 19 In this more advanced version, the maximum length of sequence homology between the vector backbone and the 293 genome was reduced down to 29 nt.
Interestingly, pIX and IVa2 expression were again unaffected by the mutations, as was capsid incorporation of the pIX monomer. Also, productivity was not affected for three different vectors that incorporated the syngen#2 sequences suggesting that incorporation of syngen#2 represents a viable and generic approach to interfere with RCA occurrence during clinical batch production.
PER.C6, an E1-transcomplementing cell line, was generated in order to eliminate overlapping sequences between the vector and cellular genomes. 9 However, PERC6 is not appropriate to produce new attenuated vectors, such as doubly ⌬E1⌬E4-defective vectors.
10 Double deletant vectors, such as ⌬E1E4 vectors are addressing some of the shortcomings of ⌬E1 vectors, specifically their limited capacity for foreign DNA, their capability for residual replication, and their provocation of immune responses. By generating an AV⌬E1E4#2 LacZ vector, we demonstrated that alterations of recombinogenic sequence within the adenovirus chromosome likely represents a viable strategy for ⌬E1E4 double-defective adenoviral vectors to reduce or abolish loss of the transgene and reacquisition of the E1 region during generation and amplification in 293-derived cell line such as IGRP2 cells. 22 
Materials and methods
Syngen#1 and syngen#2 design and synthesis
Syngen#1 and syngen#2 refer to synthetic pIX-IVa2 sequences that were introduced in the vector backbone in place of the corresponding wild-type Ad5 sequences (for sequence details see French patent application 97 14383). These synthetic sequences were synthesized by Microsynth (Balgach, Swizerland), amplified by PCR, cloned in pBSK(+) (Stratagene, La Jolla, CA, USA) and sequenced (pSyngen#1 and pSyngen#2). They display mutations scattered between Ad5 nt position 3520 and 4445, a DNA fragment that encompasses the recombinogenic sequences from 293 cells. 3 More specifically for syngen#1, a total of 185 silent mutations were introduced within the coding regions of pIX (ie between nt 3609 and 4031) and the C-terminus of IVa2 (ie between nt 4091 and 4445) according to the codon usage. Overall, this procedure was applied to 133 codons within pIX and 19 codons within the distal segment of IVa2.
Syngen#2 is another example of mutated recombinogenic pIX-IVa2, except that mutations were introduced into the pIX-IVa2 coding sequences (55 mutations), as well as the noncoding sequences, including eight point mutations scattered within the pIX promoter (nt 3520 to 3609), while the pIX-IVa2 intergenic region (nt 4031 to 4091) was replaced by that from adenovirus serotype 7.
19
Syngen#1 shuttle plasmid Plasmid pJJ105 is a pIC20H-derivative 23 containing the Ad5 sequence encompassing nt position 3446 to 5718. 24 pJJ105 was used to amplified a IVa2 sequence fragment (nt position 4446 to 4615) with oligonucleotides SyngI (AACTGCAGGCCGGCCACTAGTCGCGATGTTCCCAG CCATATCCC) and SyngII (CCGCTCGAGGTGACCG CTAGCCATCATTATGGACGAATGC harboring a NruI site at its 5' end (adenoviral sequences are underlined, the NruI site is in italic). The PCR product was inserted into the SmaI site of pIC20R to generate pJJ203, and its sequence was confirmed. The contiguous fragment of IVa2 (nt position 4593 to 5192) was BstEII filled/NsiI excised from pJJ105 before being inserted between the ClaI filled and NsiI sites of pJJ203 (pJJ204). Syngen#1 sequence was excised from pSyngen#1 by FseI/NruI and inserted between the FseI and NruI sites of pJJ204 (pJJ205). pJJ202 is a derivative of pXL2756, 17 which harbors the left inverted terminal repeat (ITR) and the packaging signal (ψ) of Ad5 (nt position 1 to 382). The overall syngen#1 fragment (ie pIX and part of IVa2 modified region) and the unmodified IVa2 sequence located downstream was excised from pJJ205 by Sse8387I/BstEII and inserted between the Sse8387I and BstEII sites of pJJ202 (pJJ206).
Viral DNA from the Ad5CMVp53 virus exhibits deletions within the E1 and E3 loci. 25 It was restricted with HindIII and the 1.3 kb fragment corresponding to its left end was purified. It was then restricted with SgrA1 and the resulting 1.1 kb fragment (referred to as insert 1) which harbors the Ad5 packaging signal and the CMV promoter of Ad5C MVp53 25 was isolated. Plasmid pIN116 is a derivative of pBS-SK (Stratagene) which contains the same CMV/p53 expression cassette as virus Ad5CMVp53. A 1.5 kb fragment (refered to as insert 2) containing the p53 cDNA and the SV40 polyadenylation signal was isolated following pIN116 restriction with HindIII and SalI. 25 Inserts 1 and 2 were ligated between the SgrAI and SalI site of pJJ206 to generate plasmid pJJ210. PJJ210 is the shuttle plasmid containing a p53 expression cassette and displaying the following sequences: ITR-ψ-CMVp53-SV40pA-syngen#1-wild-type IVa2 fragment.
Introduction of syngen#1 in the recombinant backbone pJJ210 is thus a ColE1-derived plasmid that can be used for recombinational cloning in E. coli 17 to introduce the CMV/p53 expression cassette followed by the synthetic syngen#1 sequence within a first-generation E1, E3-deleted adenoviral genome.
17
Syngen#2 shuttle plasmids A minor modification of the EDRAG technology 17 was implemented using an RK6-based shuttle plasmid instead of a ColE1-derivative. In the original EDRAG technology, recovery of the recombinant adenoviral genome required a counterselection step after homologous recombination in E. coli which resulted from the fact that bacterial plasmids displaying a colE1 replication origin could not replicate (ie survive) in a polA mutant strain of E. coli. 17 In order to simplify the procedure, we have introduced a conditional replication origin (R6K) instead of colE1, so that the selection step following homologous recombination can be carried out in standard E. coli RecA+ strains instead of using the polA mutant strain (JJ Robert, manuscript in preparation).
pIG5 is a RK6 derivative (Kmr; Sucr) that contains the left end of Ad5 (pos 1 to 382), followed by a SwaI and a SalI site. The CMV-nlslacZ expression cassette isogenic to that of pGY63 17 was inserted between the SwaI and the SalI site of pIG1 (pIG3). A fragment of the wild-type sequence of IVa2 was excised from pJJ105 by StyI/BstEII (nt position 4355 to 5199) and inserted between the StyI/BstEII sites of pJJ205 (pIG2). Syngen#2 was excised from pSyngen#2 by SalI/StyI and inserted between the SalI and StyI sites of pIG2 (pIG4). The overall fragment syngen#2 (ie pIX and part of IVa2 modified region) plus wild-type IVa2 region was excised from pIG4 by SalI/BstEII filled and inserted between the SalI and MfeI filled sites of pIG3 (pIG5). pIG5 is the shuttle plasmid containing the LacZ expression cassette and displaying the following sequences: ITR-ψ-CMVnlsLacZ-SV40pA-syngen#2-wild-type IVa2 fragment. Again, the overall fragment syngen#2 plus wild-type IVa2 region was excised from pIG4 by SalI/BstEII and inserted between the SalI and BstEII sites of pIG1 (pIG7). pIG7 is the shuttle plasmid without expression cassette and displaying the following sequences: ITR-ψ-syngen#2-wild-type IVa2 fragment. Finally, the CMV-nlsLacZ cassette from pIG5 was excised and replaced by a CMV-Luciferase sequence (pIG18). pIG18 is the shuttle plasmid containing a Luc expression cassette and displaying the following sequences: ITR-ψ-CMVLuc-SV40pA-syngen#2-wild-type IVa2 fragment.
Introduction of syngen#2 in the recombinant backbone pIG5 is a R6K-derived shuttle plasmid that was used for introducing the CMV-nlsLacZ expression cassette immediately followed by the syngen#2 sequence by homologous recombination in E. coli. These sequences were introduced within a first-generation adenoviral genome by using E1-deleted adenoviral backbone pXL2689 as a recipient plasmid, 17 generating plasmid pAd⌬E1#2-CMV-LacZ. This plasmid therefore contains a PacI-excisable adenoviral backbone in which a CMV/LacZ expression cassette is cloned in place of the E1 genes, whereas syngen#2 replaces Ad5 sequences nt 3520 to 4344 (see above).
Plasmids pIG7 and pIG18 are identical to pIG5 except that they lack an expression cassette, or display a CMVLuc expression cassette instead of CMV/LacZ, respectively. They were used as above to introduce the syngen#2 sequence within an E1-deleted adenoviral genome (plasmids pAd⌬E1#2-Empty and pAD⌬E1#2-CMV-Luc, respectively).
Introduction of the synthetic sequences within secondgeneration adenoviral backbones was similarly carried out by recombinational cloning in E. coli. For example, R6K-derived shuttle plasmids pIG5 and pIG/CMV-d1EGFP were used to introduce, respectively, the CMVnlsLacZ and CMV-d1/EGFP expression cassettes (from Clontech, Palo Alto, CA, USA) followed by the syngen#2 sequence into plasmid pXL2789, 17 generating plasmids pAd⌬E1E4#2-CMV-lacZ, and pAd⌬E1E4#2-CMV-d1GFP, respectively. As previously described, 17 these plasmids therefore contain a PacI-excisable recombinant adenoviral genome deleted in E1 (nt 382 to 3520), E3 (nt 28592 to 30470) and E4 (nt 33423 to 35356). 26 cell lines were grown and passaged as previously described. 10, 22 E1-defective and E1E4-doubly defective adenoviruses were recovered following transfection of the corresponding PacI-digested ⌬E1 and ⌬E1E4 backbones in 293 or IGRP2 cells as described. Ad5CMV-p53 and AV⌬E1CMVLacZ, AV⌬E1RSVLacZ, AV⌬E1Empty(without expression cassette) harboring wild-type pIX region have been described elsewhere. 17, 25 Purified viral stocks were prepared from intracellular lysates of infected cells as described. 10 Unless otherwise stated, viral titers were expressed as virus particles/ml as determined by optical absorbance or HPLC.
Cell lines and viruses
27 AV⌬E1#2-CMV-lacZ and AV⌬E1E4#2-CMV-lacZ were also titrated as LacZ-transducing particles (TDU) on W162 monolayers as described. 10 Virus plaques were isolated on 293 cells as described. 22 Western blotting using anti-pIX and anti-IVa2 antibodies 293 Cells infected at 300 vp/cell were collected 24 h after infection and washed twice with phosphate buffer saline (PBS). They were lysed in 50 mm Tris pH 7.9, 10 mm KCl, 0.2% NP40, 1 mm EDTA and 10% glycerol. CsCl-purified particles were disrupted by boiling in SDS sample buffer. Cellular or virion samples were then fractionated by SDS-4/12% PAGE according to the manufacturer's instructions (Nupage Electrophoresis System; Novex, San Diego, CA, USA). Proteins were then transferred on to Hybond-P membranes (Amersham) and probed with specific antibodies. Bound antibodies were detected using appropriate secondary antibodies as recommended (ECL detection system; Amersham, Piscataway, NJ, USA). Polyclonal antibobies against pIX (anti-pIX; 1:5000) and monoclonal antibodies against IVa2 (anti-IVa2; 1:10 000) were kindly provided by C Kedinger (EGBS-FRE2370, Illkirch, France). Polyclonal antibodies against Ad5-purified virions (antivirion-L5; 1:2000) were provided by F Bellot (Rhô ne-Poulenc Rorer, Vitry/Seine, France). The number of adenoviral particles loaded on to the gel was controlled using double labeling with antivirion-L5 antibodies.
Cell viability assay
The cytotoxic profile of AV⌬E1#1-CMVp53 was compared with that of Ad5CMVp53 in H1299 cells. To this end, subconfluent H1299 cells cultivated in six-well dishes were infected at an MOI of 4300 vp/cell. Duplicates of cell monolayers were then trypsinized at different times after infection, and cell viability was determined by the Trypan blue exclusion assay.
RCA detection and statistical analysis
RCA contamination was determined by a quantitative assay on A549 monolayers as described. 10 Doses of 3 × Gene Therapy 10 10 vp were used per assay. Emergence of RCA by homologous recombination is a rare event that classically follows a Poisson distribution curve. The observed numbers of RCA are below the value allowing the use of normal approximations for comparisons, hence we had to use 'exact' confidence intervals. Such intervals are generally difficult to define for some parameters, here we took advantage of the fact that the observed number was zero in one of the series. The test is then based on the assessment of the chances that, given r the total number of observed RCA in the two series, they all occurred in only one of the sets. It can be shown that the probability of this event is (1 + f) -r where r is the total number of RCA and f (Ͻ1) the ratio of the real, and unknown, numbers of RCA in the virus suspension. Following the classical definition of confidence intervals, 28 we stated that fmax (the largest value for f) is defined by (1 + fmax) -r = α for a confidence of (1Ϫα). Hence if αϪ1/r is less than 2, the number of RCA can be said to be significantly decreased with the confidence 1Ϫα, or f may be stated to be less than 1 with a P value of (1/2)r.
